TAK-981

Overview

TAK-981 is a first-in-class inhibitor of the SUMOylation enzymatic cascade being developed for the treatment of multiple myeloma.

SparkCures ID 409
Developed By Takeda Oncology
Generic Name TAK-981
Treatment Classifications
  • SUMO-activating enzyme subunit 2 (SAE2)

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.